Author

Alicia Elsing

Observed name: A. Elsing

Institution: Mayo Clinic

Observed institution: Mayo Clinic

OpenAlex ID: A5088130910

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer

2022 · Niharika B. Mettu, Fang-Shu Ou, et al. · JAMA Network Open · 129

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

2019 · N.B. Mettu, E. Twohy, et al. · Annals of Oncology · 72

Works count: 2

Citation count: 201

H-index: 2

I10-index: 2